Alinity i HBsAg Next Qualitative assay, Alinity i HBsAg Next Confirmatory assay
FDA premarket approval P210003/S006 · decided 2023-09-28
Approval details
- PMA number
- P210003
- Supplement
- S006
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- Alinity i HBsAg Next Qualitative assay, Alinity i HBsAg Next Confirmatory assay
- Generic name
- Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
- Applicant
- Abbott Laboratories
- Date received
- 2023-04-03
- Decision date
- 2023-09-28
- Days to decision
- 178 days
- Decision code
- APPR
- Product code
- LOM
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- Abbott Park, IL
- Statement
- Approval for the Migration of the Abbott ARCHITECT HBsAg Next Qualitative and ARCHITECT HBsAg Next Confirmatory assay (P210003) to the Alinity i system (referred to as the Alinity i analyzer), which will be known as the Alinity i HBsAg Next Qualitative and Alinity i HBsAg Next Confirmatory assay.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| Anti-HCV Next (K252424) | Abbott Laboratories | 2026-04-28 |
| ARCHITECT iGentamicin (K243500) | Abbott Laboratories | 2025-07-09 |
| Alinity i Rubella IgG (K243168) | Abbott Laboratories | 2025-06-20 |
| Alinity h-series System (K243283) | Abbott Laboratories | 2025-02-20 |
| Alinity i Toxo IgM (K233932) | Abbott Laboratories | 2024-08-30 |
| TBI (K232669) | Abbott Laboratories | 2023-09-29 |
| HAVAb IgG II (K222850) | Abbott Laboratories | 2023-08-10 |
| Alinity h-series System (K220031) | Abbott Laboratories | 2023-08-04 |